title: Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies.
abstract: We analyzed the clinical factors associated with late cytomegalovirus (CMV) reactivation in a group of 269 consecutive recipients of allogeneic stem cell transplant (SCT) for hematological malignancies. Eighty-four subjects (31%) experienced late CMV reactivation, including 64 with prior early reactivation and 20 with isolated late reactivation. Multivariate analyses were conducted in patients with early CMV reactivation to identify factors associated with late recurrence. Important risk factors included lymphoid diagnosis, occurrence of graft-versus-host disease (GVHD), greater number of episodes of early reactivation, persistent day 100 lymphopenia and the use of a CMV-seronegative donor graft. We combined these risk factors in a predictive model to identify those at relatively low, intermediate and high risk. The low-risk group (15% cumulative incidence, CI) encompassed patients without early CMV reactivation, and subjects transplanted for a myeloid malignancy from a matched-related (MR) donor without subsequent acute GVHD. The high-risk patients (73% CI) met all of the following criteria: (1) received an MR graft but developed GVHD, or received a non-MR graft irrespective of GVHD; (2) had more than two episodes of early reactivation; and (3) received a CMV-seronegative graft and/or remained persistently lymphopenic at day 100 after SCT. The remaining patients had an intermediate incidence of 32%.
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
authors.forename: E
authors.initials: E
authors.lastname: Ozdemir
authors.forename: R M
authors.initials: RM
authors.lastname: Saliba
authors.forename: R E
authors.initials: RE
authors.lastname: Champlin
authors.forename: D R
authors.initials: DR
authors.lastname: Couriel
authors.forename: S A
authors.initials: SA
authors.lastname: Giralt
authors.forename: M
authors.initials: M
authors.lastname: de Lima
authors.forename: I F
authors.initials: IF
authors.lastname: Khouri
authors.forename: C
authors.initials: C
authors.lastname: Hosing
authors.forename: S M
authors.initials: SM
authors.lastname: Kornblau
authors.forename: P
authors.initials: P
authors.lastname: Anderlini
authors.forename: E J
authors.initials: EJ
authors.lastname: Shpall
authors.forename: M H
authors.initials: MH
authors.lastname: Qazilbash
authors.forename: J J
authors.initials: JJ
authors.lastname: Molldrem
authors.forename: R F
authors.initials: RF
authors.lastname: Chemaly
authors.forename: K V
authors.initials: KV
authors.lastname: Komanduri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003586:Cytomegalovirus Infections / Q000209:etiology*; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy*; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012008:Recurrence; D012307:Risk Factors; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D014184:Transplantation, Homologous